News

A study designed to treat recurrent epithelial ovarian cancer looks at an antibody drug conjugate, and a second study for people with advanced breast cancer evaluates a drug that degrades estrogen rec

Walk in the shoes of security officer Patricia Varela and her K-9 partner Nix, and experience their important work to keep everyone safe at Providence Portland Medical Center.

Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.

June is National Cancer Survivor Month, but we honor people with cancer, no matter where they are on their journey, every day of the year. Find out about the survivorship program at Providence Cancer

Providence Cancer Institute presents a free virtual education event about MRI-guided radiation therapy and how it is used to treat pancreatic cancer.

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.

Explore three innovative studies targeting uveal melanoma, melanoma and head and neck squamous cell carcinoma. Learn why these studies offer hope for more effective cancer treatments.

Practice Greenhealth recognizes Providence’s commitment to environmental stewardship, names Providence a ‘System of Change’

Providence Cancer Institute researcher shares her journey to immunology and the advice she has for those seeking a career in cancer research.

Jennifer Burrows, RN, has been chosen to serve as the chief executive of Providence Oregon.

Researchers at Providence Cancer Institute are exploring a range of innovative approaches to targeting human papillomavirus-positive head and neck squamous cell cancer.

In a new clinical trial open at Providence Cancer Institute, the therapy IGM-8444 aims to promote apoptosis, potentially slowing down the growth of DR5-positive tumor cells.